Long
Endo International Bullish News | Upside Potential
Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first authorized generic versions of Mallinckrodt's Amitiza® (lubiprostone) 8 mcg and 24 mcg capsules.
According to IQVIA™, Amitiza® capsule sales were approximately $427 million for the 12 months ended September 30, 2020. (Source: prnewswire.com)
Endo International plc (NASDAQ: ENDP) announced that its subsidiary Endo Ventures Limited has entered into definitive agreements with Radius Health, Inc. (NASDAQ: RDUS) to register, commercialize and distribute abaloparatide on an exclusive basis in Canada. (Source: newswire.ca)
"We are very pleased to work with Radius to possibly bring a new treatment option to the market for Canadian osteoporosis patients," said Livio Di Francesco, Vice President and General Manager of Paladin.
Please leave me a message if you want to test the buy and sell indicators that i am using.
According to IQVIA™, Amitiza® capsule sales were approximately $427 million for the 12 months ended September 30, 2020. (Source: prnewswire.com)
Endo International plc (NASDAQ: ENDP) announced that its subsidiary Endo Ventures Limited has entered into definitive agreements with Radius Health, Inc. (NASDAQ: RDUS) to register, commercialize and distribute abaloparatide on an exclusive basis in Canada. (Source: newswire.ca)
"We are very pleased to work with Radius to possibly bring a new treatment option to the market for Canadian osteoporosis patients," said Livio Di Francesco, Vice President and General Manager of Paladin.
Please leave me a message if you want to test the buy and sell indicators that i am using.
Copy my trades: partner.bybit.com/b/best_copy_trading
BUY-SELL INDICATORS: bit.ly/indicatorz
TRADING COURSE: bit.ly/10Xtrading
STOCK OPTIONS SIGNALS: bit.ly/options_signals
BUY-SELL INDICATORS: bit.ly/indicatorz
TRADING COURSE: bit.ly/10Xtrading
STOCK OPTIONS SIGNALS: bit.ly/options_signals
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.